Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure.
Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial
Cipriani, Elisa;Sales, Gabriele;Fanelli, Vito;Brazzi, Luca;Consonni, Dario;
2019-01-01
Abstract
Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
2019 Trials Panigada.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.